Publication

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial

ANNÉE

2020

AUTEURS

Conroy T, Lamfichekh N, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, De la Fouchardière C, Juzyna B, Rullier E, Marchal F, Castan F, Borg C

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://meetings.asco.org/abstracts-presentations/185485

Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial

ANNÉE

2020

AUTEURS

C. Borg, E. Rullier, F. Marchal, P-L. Etienne, E. Rio, E. Francois, N. Mesgouez-Nebout, V. Vendrely, X. Artignan, O. Bouche, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. de la Fouchardiere, B. Juzyna, C. Mollevi, F. Castan, T. Conroy

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.annonc.2020.08.2249

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)

ANNÉE

2020

AUTEURS

Karoui M, Rullier A, Piessen G, Legoux J,L, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau J,M, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J

CONGRÈS/REVUE

Ann Surg

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1097/SLA.0000000000003454

Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years follow-up results of the Prodige 22 phase II randomized multicenter trial

ANNÉE

2020

AUTEURS

Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J, for PRODIGE 22 investigators/Collaborators

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4110

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

ANNÉE

2020

AUTEURS

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouche O, Francois E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C, PRODIGE 9 Investigators and PRODIGE 20 Investigators

CONGRÈS/REVUE

Gut

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1136/gutjnl-2018-316407

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

ANNÉE

2020

AUTEURS

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J

CONGRÈS/REVUE

Gastric Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1007/s10120-019-00983-3

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

ANNÉE

2020

AUTEURS

Turpin A, de Baere T, Heurgue A, Le Malicot K, Ollivier-Hourmand I, Lecomte T, Perrier H, Vergniol J, Sefrioui D, Rinaldi Y, Edeline J, Jouve JL, Silvain C, Becouarn Y, Dauvois B, Baconnier M, Debette-Gratien M, Deplanque G, Dharancy S, Lepage C, Hebbar M, PRODIGE 16 investigators Collaborators

CONGRÈS/REVUE

Clin Res Hepatol Gastroenterol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.clinre.2020.05.012

Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study

ANNÉE

2020

AUTEURS

Goere D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech JJ, Kianmanesh R, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Rat P, Durand-Fontanier S, Mariani P, Lakkis Z, Loi V, Pirro N, Sabbagh C, Texier M, Elias D BIG-RENAPE group

CONGRÈS/REVUE

Lancet Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/s1470-2045(20)30322-3

Traitement adjuvant des voies biliaires : qui et comment ? [Adjuvant treatment of biliary tract cancers: Who and how?]

ANNÉE

2020

AUTEURS

Edeline J

CONGRÈS/REVUE

Bull Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.bulcan.2019.12.004

Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies

ANNÉE

2020

AUTEURS

Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Monard L, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip JM, Ebata T

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.annonc.2020.08.033